Q2 FY2026 EarningsQ2 FY26 missed consensus significantly across top and bottom lines, reporting $0 revenue vs. $117.3M expected and a GAAP EPS of -$0.11 vs. $0.04 expected. The variance is primarily due to a lack of projected collaboration or licensing revenue during the quarter. To conserve capital, the company announced a 60% workforce reduction and program prioritization for efzofitimod, extending the cash runway into late 2028 with $58.9M in liquidity.